BACKGROUND: It is unclear whether supplementation with vitamin D reduces the risk of cancer or cardiovascular disease, and data from randomized trials are limited. METHODS: We conducted a nationwide, randomized, placebo-controlled trial, with a two-by-two factorial design, of vitamin D3 (cholecalciferol) at a dose of 2000 IU per day and marine n-3 (also called omega-3) fatty acids at a dose of 1 g per day for the prevention of cancer and cardiovascular disease among men 50 years of age or older and women 55 years of age or older in the United States. Primary end points were invasive cancer of any type and major cardiovascular events (a composite of myocardial infarction, stroke, or death from cardiovascular causes). Secondary end points included site-specific cancers, death from cancer, and additional cardiovascular events. This article reports the results of the comparison of vitamin D with placebo. RESULTS:A total of 25,871 participants, including 5106 black participants, underwent randomization. Supplementation with vitamin D was not associated with a lower risk of either of the primary end points. During a median follow-up of 5.3 years, cancer was diagnosed in 1617 participants (793 in the vitamin D group and 824 in the placebo group; hazard ratio, 0.96; 95% confidence interval [CI], 0.88 to 1.06; P=0.47). A major cardiovascular event occurred in 805 participants (396 in the vitamin D group and 409 in the placebo group; hazard ratio, 0.97; 95% CI, 0.85 to 1.12; P=0.69). In the analyses of secondary end points, the hazard ratios were as follows: for death from cancer (341 deaths), 0.83 (95% CI, 0.67 to 1.02); for breast cancer, 1.02 (95% CI, 0.79 to 1.31); for prostate cancer, 0.88 (95% CI, 0.72 to 1.07); for colorectal cancer, 1.09 (95% CI, 0.73 to 1.62); for the expanded composite end point of major cardiovascular events plus coronary revascularization, 0.96 (95% CI, 0.86 to 1.08); for myocardial infarction, 0.96 (95% CI, 0.78 to 1.19); for stroke, 0.95 (95% CI, 0.76 to 1.20); and for death from cardiovascular causes, 1.11 (95% CI, 0.88 to 1.40). In the analysis of death from any cause (978 deaths), the hazard ratio was 0.99 (95% CI, 0.87 to 1.12). No excess risks of hypercalcemia or other adverse events were identified. CONCLUSIONS: Supplementation with vitamin D did not result in a lower incidence of invasive cancer or cardiovascular events than placebo. (Funded by the National Institutes of Health and others; VITAL ClinicalTrials.gov number, NCT01169259 .).
RCT Entities:
BACKGROUND: It is unclear whether supplementation with vitamin D reduces the risk of cancer or cardiovascular disease, and data from randomized trials are limited. METHODS: We conducted a nationwide, randomized, placebo-controlled trial, with a two-by-two factorial design, of vitamin D3 (cholecalciferol) at a dose of 2000 IU per day and marine n-3 (also called omega-3) fatty acids at a dose of 1 g per day for the prevention of cancer and cardiovascular disease among men 50 years of age or older and women 55 years of age or older in the United States. Primary end points were invasive cancer of any type and major cardiovascular events (a composite of myocardial infarction, stroke, or death from cardiovascular causes). Secondary end points included site-specific cancers, death from cancer, and additional cardiovascular events. This article reports the results of the comparison of vitamin D with placebo. RESULTS: A total of 25,871 participants, including 5106 black participants, underwent randomization. Supplementation with vitamin D was not associated with a lower risk of either of the primary end points. During a median follow-up of 5.3 years, cancer was diagnosed in 1617 participants (793 in the vitamin D group and 824 in the placebo group; hazard ratio, 0.96; 95% confidence interval [CI], 0.88 to 1.06; P=0.47). A major cardiovascular event occurred in 805 participants (396 in the vitamin D group and 409 in the placebo group; hazard ratio, 0.97; 95% CI, 0.85 to 1.12; P=0.69). In the analyses of secondary end points, the hazard ratios were as follows: for death from cancer (341 deaths), 0.83 (95% CI, 0.67 to 1.02); for breast cancer, 1.02 (95% CI, 0.79 to 1.31); for prostate cancer, 0.88 (95% CI, 0.72 to 1.07); for colorectal cancer, 1.09 (95% CI, 0.73 to 1.62); for the expanded composite end point of major cardiovascular events plus coronary revascularization, 0.96 (95% CI, 0.86 to 1.08); for myocardial infarction, 0.96 (95% CI, 0.78 to 1.19); for stroke, 0.95 (95% CI, 0.76 to 1.20); and for death from cardiovascular causes, 1.11 (95% CI, 0.88 to 1.40). In the analysis of death from any cause (978 deaths), the hazard ratio was 0.99 (95% CI, 0.87 to 1.12). No excess risks of hypercalcemia or other adverse events were identified. CONCLUSIONS: Supplementation with vitamin D did not result in a lower incidence of invasive cancer or cardiovascular events than placebo. (Funded by the National Institutes of Health and others; VITAL ClinicalTrials.gov number, NCT01169259 .).
Authors: Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Hugo A Katus; Bertil Lindahl; David A Morrow; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Robert O Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasché; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; José-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michal Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis Journal: Circulation Date: 2012-08-24 Impact factor: 29.690
Authors: Mohamed B Elamin; Nisrin O Abu Elnour; Khalid B Elamin; Mitra M Fatourechi; Aziz A Alkatib; Jaime P Almandoz; Hau Liu; Melanie A Lane; Rebecca J Mullan; Ahmad Hazem; Patricia J Erwin; Donald D Hensrud; Mohammad Hassan Murad; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2011-06-15 Impact factor: 5.958
Authors: Andjela T Drincic; Laura A G Armas; Eileen E Van Diest; Robert P Heaney Journal: Obesity (Silver Spring) Date: 2012-01-19 Impact factor: 5.002
Authors: Joann E Manson; Shari S Bassuk; I-Min Lee; Nancy R Cook; Michelle A Albert; David Gordon; Elaine Zaharris; Jean G Macfadyen; Eleanor Danielson; Jennifer Lin; Shumin M Zhang; Julie E Buring Journal: Contemp Clin Trials Date: 2011-10-02 Impact factor: 2.226
Authors: Kerrie M Sanders; Amanda L Stuart; Elizabeth J Williamson; Julie A Simpson; Mark A Kotowicz; Doris Young; Geoffrey C Nicholson Journal: JAMA Date: 2010-05-12 Impact factor: 56.272
Authors: Judith Hsia; Gerardo Heiss; Hong Ren; Matthew Allison; Nancy C Dolan; Philip Greenland; Susan R Heckbert; Karen C Johnson; JoAnn E Manson; Stephen Sidney; Maurizio Trevisan Journal: Circulation Date: 2007-02-20 Impact factor: 29.690
Authors: Jean Wactawski-Wende; Jane Morley Kotchen; Garnet L Anderson; Annlouise R Assaf; Robert L Brunner; Mary Jo O'Sullivan; Karen L Margolis; Judith K Ockene; Lawrence Phillips; Linda Pottern; Ross L Prentice; John Robbins; Thomas E Rohan; Gloria E Sarto; Santosh Sharma; Marcia L Stefanick; Linda Van Horn; Robert B Wallace; Evelyn Whitlock; Tamsen Bassford; Shirley A A Beresford; Henry R Black; Denise E Bonds; Robert G Brzyski; Bette Caan; Rowan T Chlebowski; Barbara Cochrane; Cedric Garland; Margery Gass; Jennifer Hays; Gerardo Heiss; Susan L Hendrix; Barbara V Howard; Judith Hsia; F Allan Hubbell; Rebecca D Jackson; Karen C Johnson; Howard Judd; Charles L Kooperberg; Lewis H Kuller; Andrea Z LaCroix; Dorothy S Lane; Robert D Langer; Norman L Lasser; Cora E Lewis; Marian C Limacher; JoAnn E Manson Journal: N Engl J Med Date: 2006-02-16 Impact factor: 91.245
Authors: Joan M Lappe; Dianne Travers-Gustafson; K Michael Davies; Robert R Recker; Robert P Heaney Journal: Am J Clin Nutr Date: 2007-06 Impact factor: 7.045
Authors: Alison Avenell; Graeme S MacLennan; David J Jenkinson; Gladys C McPherson; Alison M McDonald; Puspa R Pant; Adrian M Grant; Marion K Campbell; Frazer H Anderson; Cyrus Cooper; Roger M Francis; William J Gillespie; C Michael Robinson; David J Torgerson; W Angus Wallace Journal: J Clin Endocrinol Metab Date: 2011-11-23 Impact factor: 5.958
Authors: Katherine D Crew; Garnet L Anderson; Dawn L Hershman; Mary Beth Terry; Parisa Tehranifar; Danika L Lew; Monica Yee; Eric A Brown; Sebastien S Kairouz; Nafisa Kuwajerwala; Therese Bevers; John E Doster; Corrine Zarwan; Laura Kruper; Lori M Minasian; Leslie Ford; Banu Arun; Marian Neuhouser; Gary E Goodman; Powel H Brown Journal: Cancer Prev Res (Phila) Date: 2019-05-28
Authors: Christine Rake; Clare Gilham; Laurette Bukasa; Richard Ostler; Michelle Newton; James Peto Wild; Benoit Aigret; Michael Hill; Oliver Gillie; Irwin Nazareth; Peter Sasieni; Adrian Martineau; Julian Peto Journal: Health Technol Assess Date: 2020-02 Impact factor: 4.014